Indication and Limitations of Use

Rayaldee® (calcifediol) extended-release 30 mcg capsules is indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Rayaldee is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis.

×

This website is intended for US Healthcare Professionals

Rayaldee effectively reduced iPTH

Study Design

Mean iPTH levels over time in clinical trials2*

iPTH levels declined over time with Rayaldee compared to placebo treatment (P<0.001)1,2

*Mean data from patient clinical trials do not guarantee individual results.

Mean iPTH change from baseline1

Patients achieving iPTH response (≥30% change from baseline to end of trial)1*

*Average of weeks 20, 22, 24, and 26.